ANI Pharmaceuticals Inc (ANIP) stock
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$68.55−0.58 (-0.84%)
Close on Nov 20, 2026Market cap $1.57BP/E 14.6Yield –
ANI Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ANI Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $172.99M, up 37.9% year over year. For fiscal 2025 it was $171.39M, up 258.7% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $171.39M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $171.39M | +258.7% |
| FY2024 | Dec 31, 2024 | $47.78M | -56.6% |
| FY2023 | Dec 31, 2023 | $110.09M | – |
| FY2022 | Dec 31, 2022 | -$40.08M | -5339.1% |
| FY2021 | Dec 31, 2021 | $765.00K | -91.6% |
| FY2020 | Dec 31, 2020 | $9.13M | -76.6% |
| FY2019 | Dec 31, 2019 | $39.00M | -36.4% |
| FY2018 | Dec 31, 2018 | $61.33M | +111.1% |
| FY2017 | Dec 31, 2017 | $29.05M | +26.8% |
| FY2016 | Dec 31, 2016 | $22.91M | +51.9% |
| FY2015 | Dec 31, 2015 | $15.08M | -27.9% |
| FY2014 | Dec 31, 2014 | $20.91M | – |
| FY2013 | Dec 31, 2013 | -$5.68M | – |
| FY2012 | Dec 31, 2012 | -$429.00K | – |
| FY2011 | Dec 31, 2011 | -$48.59M | – |
| FY2010 | Dec 31, 2010 | -$40.16M | – |
| FY2009 | Dec 31, 2009 | -$18.60M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $53.62M | -25.3% |
| Q1 FY2026 | Mar 31, 2026 | $52.30M | +60.8% |
| Q4 FY2025 | Dec 31, 2025 | $29.12M | +116.3% |
| Q3 FY2025 | Sep 30, 2025 | $37.95M | +395.3% |
| Q2 FY2025 | Jun 30, 2025 | $71.80M | +453.8% |
| Q1 FY2025 | Mar 31, 2025 | $32.52M | +137.6% |
| Q4 FY2024 | Dec 31, 2024 | $13.47M | -68.3% |
| Q3 FY2024 | Sep 30, 2024 | $7.66M | -74.8% |
| Q2 FY2024 | Jun 30, 2024 | $12.97M | -28.5% |
| Q1 FY2024 | Mar 31, 2024 | $13.69M | -28.2% |
| Q4 FY2023 | Dec 31, 2023 | $42.46M | – |
| Q3 FY2023 | Sep 30, 2023 | $30.43M | +2534.6% |
| Q2 FY2023 | Jun 30, 2023 | $18.13M | – |
| Q1 FY2023 | Mar 31, 2023 | $19.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.54M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.16M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.89M | -204.6% |
| Q4 FY2021 | Dec 31, 2021 | -$12.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$691.00K | -103.4% |
| Q1 FY2021 | Mar 31, 2021 | $19.97M | +11578.4% |
| Q4 FY2020 | Dec 31, 2020 | -$7.82M | -352.2% |
| Q3 FY2020 | Sep 30, 2020 | -$3.38M | -116.7% |
| Q2 FY2020 | Jun 30, 2020 | $20.16M | +548.1% |
| Q1 FY2020 | Mar 31, 2020 | $171.00K | -98.6% |
| Q4 FY2019 | Dec 31, 2019 | $3.10M | -88.2% |
| Q3 FY2019 | Sep 30, 2019 | $20.27M | +191.8% |
| Q2 FY2019 | Jun 30, 2019 | $3.11M | -58.6% |
| Q1 FY2019 | Mar 31, 2019 | $12.52M | -39.4% |
| Q4 FY2018 | Dec 31, 2018 | $26.23M | +112.2% |
| Q3 FY2018 | Sep 30, 2018 | $6.95M | -52.4% |
| Q2 FY2018 | Jun 30, 2018 | $7.51M | – |
| Q1 FY2018 | Mar 31, 2018 | $20.65M | +370.3% |
| Q4 FY2017 | Dec 31, 2017 | $12.36M | +15.6% |
| Q3 FY2017 | Sep 30, 2017 | $14.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.69M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.00K | – |
See a number that looks wrong?